A putative biomarker signature for clinically effective AKT inhibition: Correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway

Oncotarget

Volumn 6, Issue 39, 2015, Pages 41736-41749

  Cheraghchi Bashi, Azadeh ^a,b   Parker, Christine A ^a,b   Curry, Ed ^a   Salazar, Jean Frederic ^b   Gungor, Hatice ^a   Saleem, Azeem ^a,b   Cunnea, Paula ^a   Rama, Nona ^a   Salinas, Cristian ^b   Mills, Gordon B ^c   Morris, Shannon R ^d   Kumar, Rakesh ^d   Gabra, Hani ^a   Stronach, Euan A ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c UNIVERSITY OF TEXAS   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

AKT; Biomarkers; Ovarian cancer; Platinum resistance; Proteomics

Indexed keywords

ANDROGEN RECEPTOR; BIM PROTEIN; CA 125 ANTIGEN; CISPLATIN; FLUORODEOXYGLUCOSE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PROTEIN KINASE B; SYNAPTOPHYSIN; UPROSERTIB; Y BOX BINDING PROTEIN 1; AKT1S1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; DIAMINE; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MEMBRANE PROTEIN; MUC16 PROTEIN, HUMAN; MULTIPROTEIN COMPLEX; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TARGET OF RAPAMYCIN KINASE; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DISEASE MARKER; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR DYNAMICS; MOLECULAR IMAGING; MOUSE; NONHUMAN; OVARY CANCER; PHENOTYPE; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEOMICS; SIGNAL TRANSDUCTION; TUMOR BIOPSY; TUMOR VOLUME; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BIOPSY; CELL PROLIFERATION; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; ENZYMOLOGY; METABOLISM; NUDE MOUSE; OVARIAN NEOPLASMS; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PHOSPHORYLATION; PREDICTIVE VALUE; PROCEDURES; TIME FACTOR; TREATMENT OUTCOME; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BIOMARKERS, TUMOR; BIOPSY; CA-125 ANTIGEN; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DIAMINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MEMBRANE PROTEINS; MICE, NUDE; MULTIPROTEIN COMPLEXES; OVARIAN NEOPLASMS; PHENOTYPE; PHOSPHORYLATION; PREDICTIVE VALUE OF TESTS; PROTEIN KINASE INHIBITORS; PROTEOMICS; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZOLES; SIGNAL TRANSDUCTION; TIME FACTORS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84951866755     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6153     Document Type: Article

References (29)

1. Vaughan S, Coward JI, Bast RC, Jr., Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nature reviews Cancer. 2011; 11:719-725.
2. Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, Colombo N, Fowler JM, Argenta PA, De Geest K, et al. Evaluation of new platinumbased treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009; 27:1419-1425.
3. Bowtell DD. The genesis and evolution of high-grade serous ovarian cancer. Nature reviews Cancer. 2010; 10:803-808.
4. Bast RC, Jr., Mills GB. Dissecting "PI3Kness": the complexity of personalized therapy for ovarian cancer. Cancer Discov. 2012; 2:16-18.
5. Stronach EA, Chen M, Maginn EN, Agarwal R, Mills GB, Wasan H, Gabra H. DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance. Neoplasia. 2011; 13:1069-1080.
6. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nature reviews Cancer. 2009; 9:550-562.
7. Stronach EA, Cheraghchi-Bashi A, Chen M, Gabra H. Targeting the AKT pathway in ovarian cancer, vol. 1: Springer; 2011.
8. Gungor H, Saleem A, Agarwal R, Blagden SP, Michael A, Stronach EA, Chen M, Pickford E, Rama NR, Lewis YL, et al. Pharmacokinetic (PK)/pharmacodynamic (PD) analysis of escalating repeat doses of the AKT inhibitor GSK2141795 (GSK795) in patients (pts) with ovarian cancer. Journal of Clinical Oncology. 2011; 29:5064.
9. Dumble M, Crouthamel MC, Zhang SY, Schaber M, Levy D, Robell K, Liu Q, Figueroa DJ, Minthorn EA, Seefeld MA, et al. Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor. PloS one. 2014; 9:e100880.
10. Sarker D, Workman P. Pharmacodynamic biomarkers for molecular cancer therapeutics. Adv Cancer Res. 2007; 96:213-268.
11. Sarker D, Pacey S, Workman P. Use of pharmacokinetic/pharmacodynamic biomarkers to support rational cancer drug development. Biomark Med. 2007; 1:399-417.
12. Hafsi S, Pezzino FM, Candido S, Ligresti G, Spandidos DA, Soua Z, McCubrey JA, Travali S, Libra M. Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drugresistance (review). Int J Oncol. 2012; 40:639-644.
13. Burris HA, Siu LL, Infante JR, Wheler JJ, Kurkjian C, Opalinska J, Smith DA, Antal JM, Gauvin JL, Gonzalez T, et al. Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-human study. J Clin Oncol. 2011; 29:suppl; abstr 3003.
14. Chan TO, Zhang J, Rodeck U, Pascal JM, Armen RS, Spring M, Dumitru CD, Myers V, Li X, Cheung JY, et al. Resistance of Akt kinases to dephosphorylation through ATP-dependent conformational plasticity. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108:E1120-1127.
15. Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, Majumder PK, Baselga J, Rosen N. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer cell. 2011; 19:58-71.
16. Lin K, Lin J, Wu WI, Ballard J, Lee BB, Gloor SL, Vigers GP, Morales TH, Friedman LS, Skelton N, et al. An ATPsite on-offswitch that restricts phosphatase accessibility of Akt. Science signaling. 2012; 5:ra37.
17. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer research. 2006; 66:1500-1508.
18. Okuzumi T, Fiedler D, Zhang C, Gray DC, Aizenstein B, Hoffman R, Shokat KM. Inhibitor hijacking of Akt activation. Nature chemical biology. 2009; 5:484-493.
19. Lin HK, Yeh S, Kang HY, Chang C. Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proceedings of the National Academy of Sciences of the United States of America. 2001; 98:7200-7205.
20. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nature reviews Genetics. 2006; 7:606-619.
21. Bader AG, Vogt PK. Phosphorylation by Akt disables the anti-oncogenic activity of YB-1. Oncogene. 2008; 27:1179-1182.
22. Evdokimova V, Ruzanov P, Anglesio MS, Sorokin AV, Ovchinnikov LP, Buckley J, Triche TJ, Sonenberg N, Sorensen PH. Akt-mediated YB-1 phosphorylation activates translation of silent mRNA species. Molecular and cellular biology. 2006; 26:277-292.
23. Sinnberg T, Sauer B, Holm P, Spangler B, Kuphal S, BosserhoffA, Schittek B. MAPK and PI3K/AKT mediated YB-1 activation promotes melanoma cell proliferation which is counteracted by an autoregulatory loop. Experimental dermatology. 2012; 21:265-270.
24. Yan Y, Serra V, Prudkin L, Scaltriti M, Murli S, Rodriguez O, Guzman M, Sampath D, Nannini M, Xiao Y, et al. Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068. Clinical cancer research: an official journal of the American Association for Cancer Research. 2013; 19:6976-6986.
25. Stronach EA, Alfraidi A, Rama N, Datler C, Studd JB, Agarwal R, Guney TG, Gourley C, Hennessy BT, Mills GB, et al. HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. Cancer research. 2011; 71:4412-4422.
26. Tibes R, Qiu Y, Lu Y, Hennessy B, AndreeffM, Mills GB, Kornblau SM. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther. 2006; 5:2512-2521.
27. Carey MS, Agarwal R, Gilks B, Swenerton K, Kalloger S, Santos J, Ju Z, Lu Y, Zhang F, Coombes KR, et al. Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy. Clinical cancer research: an official journal of the American Association for Cancer Research. 2010; 16:2852-2860.
28. Hong F, Breitling R, McEntee CW, Wittner BS, Nemhauser JL, Chory J. RankProd: a bioconductor package for detecting differentially expressed genes in meta-analysis. Bioinformatics. 2006, 22:2825-2827.
29. Irizarry RA, Wang C, Zhou Y, Speed TP. Gene set enrichment analysis made simple. Statistical methods in medical research. 2009; 18:565-575.